Cosmo NVCMOPF -3.22%82 Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $54.86 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 685 Drug Manufacturers companies, Cosmo NV ranks worse than 145985.26% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Cosmo NV's
Operating Income
for the
six
months ended in Dec. 2025 was $-6.5 Mil. Cosmo NV's Interest Expense for the
six
months ended in Dec. 2025 was $-0.1 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Cosmo NV's Interest Coverage or its related term are showing as below:
CMOPF's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.78 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Cosmo NV Interest Coverage Related Terms
Cosmo NV Interest Coverage Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CMOPF vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Cosmo NV did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Cosmo NV (CMOPF) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Cosmo NV and its competitors. According to the industry distribution chart, Cosmo NV ranks #999999 out of 685 companies in the Drug Manufacturers industry.
Is Cosmo NV's Interest Coverage too high?
Cosmo NV's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Cosmo NV ranks #999999 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #999999 out of 685 companies for Interest Coverage. This places Cosmo NV in the lower half of its industry. The industry median Interest Coverage is 12.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.86, compared to a current price of $82.00 — trading 49.5% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $82.00 is trading 49.5% above its estimated GF Value™ of $54.86.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Interest Coverage: 0 (At Loss)
GF Value™: $54.86 vs. price of $82.00 (49.5% above fair value)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score
Get the complete analysis for CMOPF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
